Biotech Insider Selling, Portola Pharmaceuticals Inc, NASDAQ:PTLA, Synageva BioPharma Corp,NASDAQ:GEVA, BioCryst Pharmaceuticals,NASDAQ:BCRX, Alnylam Pharmaceuticals, NASDAQ:ALNY, Jazz Pharmaceuticals plc – Ordinary Shares, NASDAQ:JAZZ,PTLA, GEVA, BCRX,ALNY, JAZZ
Portola Pharmaceuticals (NASDAQ:PTLA) EVP John T. Curnutte sold 30,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $28.33, for a total transaction of $849,900.00. Portola Pharmaceuticals Inc (NASDAQ:PTLA) weekly performance is 19.43%. On last trading day company shares ended up $29.87. Analysts mean target price for the company is $38.50. Portola Pharmaceuticals Inc (NASDAQ:PTLA) distance from 50-day simple moving average (SMA50) is 28.58%.
Synageva BioPharma Corp (NASDAQ:GEVA) Director Barry D. Quart sold 1,000 shares of the stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $83.31, for a total transaction of $83,310.00. Synageva BioPharma Corp (NASDAQ:GEVA) shares advanced 2.42% in last trading session and ended the day on $97.46. GEVA its return on assets is -25.10%. Synageva BioPharma Corp (NASDAQ:GEVA) quarterly performance is -2.71%.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved down -2.19% in last trading session and was closed at $11.62, while trading in range of $11.46 – $12.07. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) year to date (YTD) performance is 52.89%.
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Akshay Vaishnaw unloaded 10,625 shares of the company’s stock on the open market in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $69.82, for a total transaction of $741,837.50. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ended the last trading day at $70.20. Company weekly volatility is calculated as 3.66% and price to cash ratio as 7.97. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) showed a positive weekly performance of 3.62%.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 5,000 shares of the stock on the open market in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $142.34, for a total transaction of $711,700.00. Following the sale, the chief executive officer now directly owns 602,067 shares of the company’s stock, valued at approximately $85,698,217. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares moved down –1.60% in last trading session and was closed at $149.59, while trading in range of $147.64 – $153.04. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) year to date (YTD) performance is 18.20%.